Axillary Management: How Much Is Too Much?
- PMID: 38748364
- PMCID: PMC11224108
- DOI: 10.1007/s11912-024-01539-0
Axillary Management: How Much Is Too Much?
Abstract
Purpose of review: To review the current management of the axilla in breast cancer.
Recent findings: Axillary dissection is no longer indicated in patients with clinically node-negative axilla with 1-2 positive sentinel lymph nodes following upfront surgery or in patients with clinically node-negative axilla following neoadjuvant chemotherapy. Breast cancer has evolved away from routine axillary clearance to the less invasive sentinel lymph node biopsy to now complete omission of axillary sampling in select patients. We will review the most salient evidence that has shaped these practice changes over the last three decades. Current practice controversies are especially relevant for elderly populations and those receiving neoadjuvant therapy. Ongoing clinical trials will provide data to further guide breast cancer surgical management.
Keywords: Axilla; Breast Cancer; Neoadjuvant Systemic Therapy; Nodal Irradiation; Surgery.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
The authors declare no competing interests.
Figures
References
-
- American Cancer Society: Breast Cancer Facts & Figures 2022-2024, Cancer Facts & Figures 2023. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-... and https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-....
-
- Cobb A, Singh P, Teshome M. Invasive Breast Cancer. The MD Anderson Surgical Oncology Manual, edited by Barry Feig, Wolters Kluwer. 2023;27–50.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
